Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Stevanato Group S.p.A. ("Stevanato" or
ATLANTA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Stevanato Group S.p.A. ("Stevanato" or the "Company") (NYSE:STVN) complied with federal securities laws. On
Investigation centers on the November 3, 2026 news about Stevanato Group S.p.A.; investors with losses may have potential claims to recover them
Stevanato Group S.p.A. ("Stevanato" or the "Company")
Investigation follows the November 3, 2026 disclosure regarding Stevanato Group S.p.A.; investors who lost money may have claims to recover their losses
Investors who lost money on Stevanato Group S.p.A.
Investigation comes after a November 3, 2026 report concerning Stevanato Group S.p.A.; shareholders who suffered losses may have claims to recover themInvestors who suffered losses on Stevanato Group S.p.A.
PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Stevanato Group S.p.A. ("Stevanato" or the "Company")
STVN shares fell on November 3, 2026, as the market reacted to a lower GLP-1 revenue outlook in Stevanato Group's pre-market third-quarter results, the issue previews had flagged as the quarter's key test.
The Company Maintains Fiscal Year 2026 Guidance
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and
Joint system-level testing combines Stevanato Group’s glass syringes with Aptar Pharma’s elastomer components to provide key data earlier in development and help inform packaging decisions for sensitive biologics and
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it
- The Company Divests its California-Based Subsidiary, Balda C. Brewer, Inc -
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the
The regulatory approvals cover therapies for diabetes and weight management, further expanding the commercial adoption of Stevanato Group's proprietary Alina® pen injector platform across Europe.
Stevanato Group
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it
The fixed-dose, multi-use pen injector platform features a pull-push mechanism designed to reduce use error while supporting delivery volumes up to 0.75 mL
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider
